Involvement of mitochondrial dynamics in the antineoplastic activity of cisplatin in murine leukemia L1210 cells

Han,Xiao-Jian; Shi,Sheng-Lan; Wei,Yong-Fang; Jiang,Li-Ping; Guo,Miao-Yu; Wu,Hong-Li; Wan,Yu-Ying

doi:10.3892/or.2017.5765

Involvement of mitochondrial dynamics in the antineoplastic activity of cisplatin in murine leukemia L1210 cells

Authors:
- Xiao-Jian Han
- Sheng-Lan Shi
- Yong-Fang Wei
- Li-Ping Jiang
- Miao-Yu Guo
- Hong-Li Wu
- Yu-Ying Wan
View Affiliations

Affiliations: Department of Intra-Hospital Infection Management, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Research Institute of Ophthalmology and Visual Sciences, Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Pharmacology, School of Pharmaceutical Sciences, Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: June 28, 2017 https://doi.org/10.3892/or.2017.5765
Pages: 985-992

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leukemia is a type of hematopoietic stem cell malignant cloned disease with high mortality. Cisplatin-based chemotherapy is one of the most common treatments for leukemia. Similar to other chemotherapeutic agents, cisplatin resistance has become a serious issue in cancer therapy. In the present study, we investigated the role of mitochondrial dynamics in the antineoplastic activity of cisplatin in murine leukemia L1210 cells. Firstly, the L1210 cell line resistant to cisplatin (L1210/DDP) was established. Compared to its parental cell line, the IC50 value of cisplatin in the L1210/DDP cells was increased 10-fold. Mitofusins (Mfn1 and Mfn2), mitochondrial outer membrane fusion proteins, were markedly upregulated in the L1210/DDP cells, whereas the expression of fission protein Drp1 and inner membrane fusion protein OPA1 were not significantly altered. In addition, mitofusins were also upregulated in the parental L1210 cells subjected to cisplatin stress. To investigate the role of mitochondrial dynamics in the antineoplastic activity of cisplatin, the effect of mitochondrial division inhibitor (Mdivi)-1 on cisplatin‑induced cell death, caspase-3 cleavage and ROS production was examined in L1210 cells. We found that 5 µM of Mdivi-1 efficiently attenuated cisplatin-induced cell death, caspase activation and intracellular ROS increase in L1210 cells. Our data indicated that mitochondrial dynamics play an important role in the antineoplastic activity of cisplatin, and mitofusin-mediated mitochondrial fusion may be involved in the process of cisplatin resistance in leukemia cells. Therefore, the present study revealed that mitochondrial dynamics may be a potential target used to improve the antineoplastic activity of cisplatin in leukemia in the future.

View Figures

View References

1	Benton CB, Nazha A, Pemmaraju N and Garcia-Manero G: Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol. 95:222–242. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chavez-Gonzalez A, Bakhshinejad B, Pakravan K, Guzman ML and Babashah S: Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cell Oncol. 40:1–20. 2017. View Article : Google Scholar
3	Calado RT and Young NS: Telomere maintenance and human bone marrow failure. Blood. 111:4446–4455. 2008. View Article : Google Scholar : PubMed/NCBI
4	Safe S, Jin UH, Hedrick E, Reeder A and Lee SO: Minireview: Role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol. 28:157–172. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chen BA, Huang ZH, Zhang XP, Ou-Yang J, Li JY, Zhai YP, Sun XM, Xu YL, Lu Q, Wang JM, et al: An epidemiological investigation of leukemia incidence between 2003 and 2007 in Nanjing, China. J Hematol Oncol. 3:212010. View Article : Google Scholar : PubMed/NCBI
6	Welch HG and Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 321:807–812. 1989. View Article : Google Scholar : PubMed/NCBI
7	Lenarsky C and Parkman R: Bone marrow transplantation for the treatment of immune deficiency states. Bone Marrow Transplant. 6:361–369. 1990.PubMed/NCBI
8	Godder KT, Abhyankar SH, Lamb LS, Best RG, Geier SS, Pati AR, Gee AP and Henslee-Downey PJ: Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant. Bone Marrow Transplant. 22:111–113. 1998. View Article : Google Scholar : PubMed/NCBI
9	Kobayashi T, Yoshida J, Ishiyama J, Noda S, Kito A and Kida Y: Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors. An experimental and clinical study. J Neurosurg. 70:676–681. 1989. View Article : Google Scholar : PubMed/NCBI
10	Borst P, Rottenberg S and Jonkers J: How do real tumors become resistant to cisplatin? Cell Cycle. 7:1353–1359. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wong E and Giandomenico CM: Current status of platinum-based antitumor drugs. Chem Rev. 99:2451–2466. 1999. View Article : Google Scholar : PubMed/NCBI
12	Milacic V, Fregona D and Dou QP: Gold complexes as prospective metal-based anticancer drugs. Histol Histopathol. 23:101–108. 2008.PubMed/NCBI
13	Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet. 2:672011. View Article : Google Scholar : PubMed/NCBI
14	Wu Y, Bhattacharyya D, King CL, Baskerville-Abraham I, Huh SH, Boysen G, Swenberg JA, Temple B, Campbell SL and Chaney SG: Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: Comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry. 46:6477–6487. 2007. View Article : Google Scholar : PubMed/NCBI
15	Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, Schlattau A, Lathroum L and Windebank AJ: Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 41:661–668. 2011. View Article : Google Scholar : PubMed/NCBI
16	Oakes SA and Korsmeyer SJ: Untangling the web: Mitochondrial fission and apoptosis. Dev Cell. 7:460–462. 2004. View Article : Google Scholar : PubMed/NCBI
17	Szabadkai G, Simoni AM, Chami M, Wieckowski MR, Youle RJ and Rizzuto R: Drp-1-dependent division of the mitochondrial network blocks intraorganellar Ca²⁺ waves and protects against Ca²⁺-mediated apoptosis. Mol Cell. 16:59–68. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shaw JM and Nunnari J: Mitochondrial dynamics and division in budding yeast. Trends Cell Biol. 12:178–184. 2002. View Article : Google Scholar : PubMed/NCBI
19	Wan YY, Zhang JF, Yang ZJ, Jiang LP, Wei YF, Lai QN, Wang JB, Xin HB and Han XJ: Involvement of Drp1 in hypoxia-induced migration of human glioblastoma U251 cells. Oncol Rep. 32:619–626. 2014.PubMed/NCBI
20	Chan DC: Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol. 22:79–99. 2006. View Article : Google Scholar : PubMed/NCBI
21	Santin G, Piccolini VM, Barni S, Veneroni P, Giansanti V, Dal Bo V, Bernocchi G and Bottone MG: Mitochondrial fusion: A mechanism of cisplatin-induced resistance in neuroblastoma cells? Neurotoxicology. 34:51–60. 2013. View Article : Google Scholar : PubMed/NCBI
22	Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S, Lee KW, Suh JY, Lee HJ and Tsang BK: Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem. 288:23740–23750. 2013. View Article : Google Scholar : PubMed/NCBI
23	Kato S, Ideguchi H, Muta K, Nishimura J and Nawata H: Mechanisms involved in the development of adriamycin resistance in human leukemic cells. Leuk Res. 14:567–573. 1990. View Article : Google Scholar : PubMed/NCBI
24	Zwelling LA, Michaels S, Schwartz H, Dobson PP and Kohn KW: DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and _L-phenylalanine mustard. Cancer Res. 41:640–649. 1981.PubMed/NCBI
25	Horvathova K, Novotny L and Vachalkova A: The free radical scavenging activity of four flavonoids determined by the comet assay. Neoplasma. 50:291–295. 2003.PubMed/NCBI
26	Choi YM, Kim HK, Shim W, Anwar MA, Kwon JW, Kwon HK, Kim HJ, Jeong H, Kim HM, Hwang D, et al: Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One. 10:e01350832015. View Article : Google Scholar : PubMed/NCBI
27	Kaushal GP, Kaushal V, Hong X and Shah SV: Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 60:1726–1736. 2001. View Article : Google Scholar : PubMed/NCBI
28	Bai J, He A, Huang C, Yang J, Zhang W, Wang J, Yang Y, Zhang P, Zhang Y and Zhou F: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia. Proteome Sci. 12:492014. View Article : Google Scholar : PubMed/NCBI
29	Muggia F: Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer. Gynecol Oncol. 112:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
30	Prestayko AW, D'Aoust JC, Issell BF and Crooke ST: Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 6:17–39. 1979. View Article : Google Scholar : PubMed/NCBI
31	Lebwohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer. 34:1522–1534. 1998. View Article : Google Scholar : PubMed/NCBI
32	Galanski M: Recent developments in the field of anticancer platinum complexes. Recent Patents Anticancer Drug Discov. 1:285–295. 2006. View Article : Google Scholar
33	Chen H and Chan DC: Physiological functions of mitochondrial fusion. Ann NY Acad Sci. 1201:21–25. 2010. View Article : Google Scholar : PubMed/NCBI
34	Renault TT, Floros KV, Elkholi R, Corrigan KA, Kushnareva Y, Wieder SY, Lindtner C, Serasinghe MN, Asciolla JJ, Buettner C, et al: Mitochondrial shape governs BAX-induced membrane permeabilization and apoptosis. Mol Cell. 57:69–82. 2015. View Article : Google Scholar : PubMed/NCBI
35	Brooks C, Wei Q, Feng L, Dong G, Tao Y, Mei L, Xie ZJ and Dong Z: Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci USA. 104:11649–11654. 2007. View Article : Google Scholar : PubMed/NCBI
36	Whelan RS, Konstantinidis K, Wei AC, Chen Y, Reyna DE, Jha S, Yang Y, Calvert JW, Lindsten T, Thompson CB, et al: Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci USA. 109:6566–6571. 2012. View Article : Google Scholar : PubMed/NCBI
37	Wen S, Zhu D and Huang P: Targeting cancer cell mitochondria as a therapeutic approach. Future Med Chem. 5:53–67. 2013. View Article : Google Scholar : PubMed/NCBI
38	Tanaka A and Youle RJ: A chemical inhibitor of DRP1 uncouples mitochondrial fission and apoptosis. Mol Cell. 29:409–410. 2008. View Article : Google Scholar : PubMed/NCBI
39	Han XJ, Yang ZJ, Jiang LP, Wei YF, Liao MF, Qian Y, Li Y, Huang X, Wang JB, Xin HB, et al: Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells. Int J Oncol. 46:691–700. 2015.PubMed/NCBI
40	Kim H, Lee JY, Park KJ, Kim WH and Roh GS: A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci. 17:332016. View Article : Google Scholar : PubMed/NCBI
41	Akita M, Suzuki-Karasaki M, Fujiwara K, Nakagawa C, Soma M, Yoshida Y, Ochiai T, Tokuhashi Y and Suzuki-Karasaki Y: Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis. Int J Oncol. 45:1901–1912. 2014.PubMed/NCBI
42	Han XJ, Lu YF, Li SA, Kaitsuka T, Sato Y, Tomizawa K, Nairn AC, Takei K, Matsui H and Matsushita M: CaM kinase I alpha-induced phosphorylation of Drp1 regulates mitochondrial morphology. J Cell Biol. 182:573–585. 2008. View Article : Google Scholar : PubMed/NCBI